Main Menu

The developed technology is a high-affinity polyclonal antibody targeting BST-2, a crucial surface antigen involved in restricting the replication of HIV-1 and other enveloped viruses. This antibody, generated from recombinant BST-2 ectodomain protein, offers versatility in various research techniques, such as FACS, immunoblotting, immunofluorescence, and immunoprecipitation. Additionally, it exhibits bioactivity, effectively inhibiting BST-2 function in virus-producing cells.

This groundbreaking technology entails the utilization of genetically modified mice, specifically engineered to enable the non-destructive detection and isolation of cells actively transcribing the IL-4 and IL-13 genes. By expressing Amcyan and DsRed-DR fluorescent proteins under the control of these gene loci, researchers gain a powerful tool for studying cytokine gene expression without the need for cell death, offering significant advantages over traditional intracellular staining methods.

This technology introduces a groundbreaking method for discovering and isolating anti-idiotypic antibodies, with a primary focus on inhibiting or extinguishing the activity of VRCOl, a broadly neutralizing anti-HIV-1 antibody. These anti-idiotypic antibodies provide a vital mechanism for controlling adverse events that may result from therapeutic antibody administration. The innovative method involves immunizing animals with specific antibody fragments, followed by systematic selection and isolation of somatically mutated B cells.

The technology involves the development of monoclonal antibodies produced by hybridomas, including cell lines such as 10G3, 3E6, 10D4, 10G4, 1D8, 13D10, 9E5, and 9F10, which specifically react with Bacillus anthracis Lethal Factor (LF). These monoclonal antibodies offer valuable applications in anthrax detection, therapeutic intervention, and research into the biology of Bacillus anthracis and its lethal toxin. This advancement provides promising tools for mitigating the impact of anthrax infections and advancing our understanding of this deadly pathogen.

This technology includes human F(ab’)2 fragments specific for anthrax lethal factor for the development of a lateral flow immunoassay for Bacillus anthracis Lethal Factor. The F(ab’)2 fragments are generated from a Human Combinatorial Antibody Library (HuCAL) and are highly specific with high affinity. A multi-step process was utilized beginning by screening a phage display library with over 45 billion functional human antibody specificities. The primary screen against Bacillus anthracis Lethal Factor (LF) generated 360 positive clones.

This technology includes a real-time RT-PCR (reverse transcriptase – polymerase chain reaction) Taqman assay using primers and probes specific for EV-D68 viral protein 1 nucleic acid. This assay provides a more specific identification of EV-D68 strains allowing better diagnosis. Human Enterovirus D68 (EV-D68) is a non-polio enterovirus that can cause mild to severe respiratory illness, especially in infants and children with asthma. The assay is simple, validated, and allows rapid testing and detection of EV-D68 in respiratory samples.

This technology includes plasmodium falciparum parasites (PH1, Benin, FCQ79, Santa Lucia and Borneo) which have all been isolated from infected persons from various geographic locations and have been modified/adapted for growth in the laboratory for multiple uses. Plasmodium falciparum strain W2 is a parasite clone from a parasite isolate called Indochina III/CDC which in turn originated from a patient in Laos infected with chloroquine-resistant parasites. Gametocytes from W2 can be grown experimentally and used in experimental infection of chimpanzees and aotus monkeys.

This technology includes an optimized influenza A/H9 virus real-time (RT)-PCR assay for detection and characterization influenza A/H9 viruses, which are considered to be one of the most likely candidates to cause an influenza pandemic in humans. The H9 real-time RT-PCR assay will be in compliment with CDC human Influenza Viruses RT-PCR Detection and Characterization Panel to detect of A/H9 influenza viruses.

This technology includes an optimized N.A H7 influenza A virus subtyping real-time (RT)-PCR assay for detection and characterization of N.A A/H7 influenza viruses. Since 1995, infection of poultry with N.A A/H7 influenza viruses has greatly increased, the outbreaks of N.A A/H7 influenza viruses in poultry as well as wild birds occurred many times in Canada, Mexico and USA; meanwhile a number of human infection caused by N.A A/H7 influenza viruses have been confirmed following exposure to infected poultry.

This technology includes a HIV-2 plasmid library for use in diagnostic assay development. In December of 2012, the Centers for Disease Control and Prevention (CDC) and the Association of Public Health Laboratories (APHL) proposed a new US laboratory testing algorithm for the diagnosis of HIV infections. This new algorithm recommends additional testing for confirmation of HIV infection using a nucleic acid amplification test (NAAT) in the event of discordant serological test results.